Inventor · disambiguated record
Thomas Wickham
Also filed as: WICKHAM THOMAS · WICKHAM THOMAS J · WICKHAM THOMAS JOSEPH
37 granted patents·27 pending applications·2,132 citations·filing 1980–2023
98Inventor score
Files withGENVEC INC18MERRIMACK PHARMACEUTICALS INC17RUBIUS THERAPEUTICS INC8SILVER CREEK PHARMACEUTICALS INC7CORNELL RES FOUNDATION INC5
Top patents by PatentIndex Score
64 records- 0198US5846782ATargeting adenovirus with use of constrained peptide motifsGENVEC INC·Filed 1996·Granted Dec 8, 1998·336 cites·24 claims
- 0295US9238080B2Bi-specific fusion proteinsNIELSEN ULRIK·Filed 2011·Granted Jan 19, 2016·29 cites·21 claims
- 0395US6740525B2Adenoviral capsid containing chimeric protein IXGENVEC INC·Filed 2001·Granted May 25, 2004·58 cites·46 claims
- 0495US6057155ATargeting adenovirus with use of constrained peptide motifsGENVEC INC·Filed 1998·Granted May 2, 2000·130 cites·36 claims
- 0595US5770442AChimeric adenoviral fiber protein and methods of using sameCORNELL RES FOUNDATION INC·Filed 1995·Granted Jun 23, 1998·173 cites·89 claims
- 0694US10988547B2Bi-specific fusion proteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2019·Granted Apr 27, 2021·6 cites·7 claims
- 0794US9718892B2Method of treating myocardial infarction by administering a bi-specific fusion proteinMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted Aug 1, 2017·12 cites·10 claims
- 0894US8691771B2Bi-specific fusion proteins for tissue repairNIELSEN ULRIK·Filed 2011·Granted Apr 8, 2014·21 cites·9 claims
- 0994US6649407B2Targeting adenovirus with use of constrained peptide motifsGENVEC INC·Filed 2001·Granted Nov 18, 2003·31 cites·21 claims
- 1094US6127525AChimeric adenoviral coat protein and methods of using sameCORNELL RES FOUNDATION INC·Filed 1997·Granted Oct 3, 2000·139 cites·48 claims
- 1194US5965541AVectors and methods for gene transfer to cellsGENVEC INC·Filed 1995·Granted Oct 12, 1999·163 cites·62 claims
- 1294US5731190APenton base protein and methods of using sameGENVEC INC·Filed 1996·Granted Mar 24, 1998·123 cites·23 claims
- 1394US5712136AAdenoviral-mediated cell targeting commanded by the adenovirus penton base proteinGENVEC INC·Filed 1996·Granted Jan 27, 1998·140 cites·52 claims
- 1494US5559099APenton base protein and methods of using sameGENVEC INC·Filed 1994·Granted Sep 24, 1996·269 cites·35 claims
- 1593US10858450B2Bi-specific fusion proteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2018·Granted Dec 8, 2020·6 cites·7 claims
- 1693US10407512B2Bi-specific fusion proteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2017·Granted Sep 10, 2019·9 cites·8 claims
- 1792US9511155B2Compositions and methods for non-invasive imagingMERRIMACK PHARMACEUTICALS INC·Filed 2013·Granted Dec 6, 2016·10 cites·19 claims
- 1892US6951755B2Vectors and methods for gene transferGENVEC INC·Filed 2001·Granted Oct 4, 2005·20 cites·15 claims
- 1991US9982060B2Bi-specific fusion proteinsMERRIMACK PHARMACEUTICALS INC·Filed 2014·Granted May 29, 2018·9 cites·15 claims
- 2091US5962311AShort-shafted adenoviral fiber and its useGENVEC INC·Filed 1996·Granted Oct 5, 1999·109 cites·60 claims
- 2190US11814443B2Bi-specific fusion proteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2021·Granted Nov 14, 2023·1 cites·20 claims
- 2289US6329190B1Targetting adenovirus with use of constrained peptide motifsGENVEC INC·Filed 1999·Granted Dec 11, 2001·60 cites·20 claims
- 2389US2024101713A1Bi-Specific Fusion ProteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2488US11673970B2Bi-specific fusion proteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2020·Granted Jun 13, 2023·1 cites·7 claims
- 2588US6455314B1Alternatively targeted adenovirusGENVEC INC·Filed 1999·Granted Sep 24, 2002·82 cites·60 claims
- 2687US6153435ANucleic acid that encodes a chimeric adenoviral coat proteinCORNELL RES FOUNDATION INC·Filed 1999·Granted Nov 28, 2000·64 cites·32 claims
- 2787US2023322951A1Bi-Specific Fusion ProteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2886US11141433B2Therapeutic cell systems and methods for treating cancer and infectious diseasesRUBIUS THERAPEUTICS INC·Filed 2019·Granted Oct 12, 2021·2 cites·30 claims
- 2986US6465253B1Vectors and methods for gene transfer to cellsGENVEC INC·Filed 1996·Granted Oct 15, 2002·53 cites·33 claims
- 3084US6756044B1Antigenic complexes and methodsGENVEC INC·Filed 2000·Granted Jun 29, 2004·11 cites·43 claims
- 3178US6576456B2Chimeric adenovirus fiber proteinCORNELL RES FOUNDATION INC·Filed 1999·Granted Jun 10, 2003·31 cites·21 claims
- 3270US9226966B2Dosage and administration for preventing cardiotoxicity in treatment with ERBB2-targeted immunoliposomes comprising anthracycline chemotherapeutic agentsMERRIMACK PHARMACEUTICALS INC·Filed 2013·Granted Jan 5, 2016·2 cites·10 claims
- 3368US6998263B2Methods of preparing and using a viral vector libraryGENVEC INC·Filed 2001·Granted Feb 14, 2006·3 cites·6 claims
- 3468US4316321AMethod and apparatus for aligning and press-fitting connector terminals into a substrateMAGNETIC PERIPHERALS INC·Filed 1980·Granted Feb 23, 1982·18 cites·13 claims
- 3566US2016067182A1Methods and compositions for improving outcomes of liposomal chemotherapyMERRIMACK PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 3664US2022088076A1Therapeutic Cell Systems and Methods for Treating Cancer and Infectious DiseasesRUBIUS THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3760US9968694B2Compositions and methods for non-invasive imagingMERRIMACK PHARMACEUTICALS INC·Filed 2016·Granted May 15, 2018·0 cites·20 claims
- 3859US2017231911A1Methods and compositions for improving outcomes of liposomal chemotherapyMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 3959US2003166286A1Chimeric adenoviral fiber protein and methods of using sameCORNELL RES FOUNDATION INC·Filed 2002·Application pending·0 cites
- 4058US2021290682A1Functionalized Erythroid CellsRUBIUS THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4157US2010330029A1Cancer Treatments with Radiation and ImmunocytokinesMERCK PATENT GMBH·Filed 2009·Application pending·0 cites
- 4257US2005277193A1Vectors and methods for gene transferGENVEC INC·Filed 2005·Application pending·0 cites
- 4356US2004167088A1Method of using adenoviral vectors with increased persistence in vivoGENVEC INC·Filed 2003·Application pending·0 cites
- 4455US2016303264A1Liposomes useful for non-invasive imaging and drug deliveryMERRIMACK PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 4552US2006140909A1Method of using adenoviral vectors with increased persistence in vivoFUSO PHARMACEUTICAL IND·Filed 2005·Application pending·0 cites
- 4652US2016184227A1Methods and compositions for improving outcomes of liposomal chemotherapyMERRIMACK PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 4752US2020172597A1Artificial antigen presenting cells including hla-e and hla-g molecules and methods of useRUBIUS THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4850US9610249B2Dosage and administration for preventing cardiotoxicity in treatment with ERbB2-targeted immunoliposomes comprising anthracycline chemotherapeutic agentsMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted Apr 4, 2017·0 cites·22 claims
- 4949US2017189335A1Dosage and administration for preventing cardiotoxicity in treatment with erbb2-targeted immunoliposomes comprising anthracycline chemotherapeutic agentsMERRIMACK PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 5049US2003099619A1Method and composition for targeting an adenoviral vectorGENVEC INC·Filed 2002·Application pending·0 cites
Showing the top 50 of 64 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →